Author

Chris Williams

Institutions: Royal Liverpool and Broadgreen University Hospital NHS Trust, University of Oxford, Broadgreen Hospital, Jenner Institute, Liverpool University Hospitals NHS Foundation Trust

Observed institutions: University of Washington, Royal Liverpool and Broadgreen University Hospital NHS Trust, University of Oxford, Broadgreen Hospital, Jenner Institute, Liverpool University Hospitals NHS Foundation Trust

ORCID: 0000-0003-2236-5644

Observed ORCID: 0000-0003-2236-5644

OpenAlex ID: A5008215906

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

2022 · Saye H Khoo, Richard FitzGerald, et al. · The Lancet Infectious Diseases · 83

Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings

2022 · Charles Mulamba, Chris Williams, et al. · Malaria Journal · 27

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

2021 · Marija Zaric, Arianna Marini, et al. · Frontiers in Immunology · 10

A systems biology approach revealed distinct host responses between ALVAC-SIV and NYVAC-SIV vaccines during an evaluation of immunogenicity in rhesus macaques (VAC7P.992)

2014 · Yajie Yang, Shari Gordon, et al. · The Journal of Immunology

Works count: 4

Citation count: 120

H-index: 3

I10-index: 3